Catalist:42CPharmaceuticals
iX Biopharma (Catalist:42C) Revenue Growth Clashes With Wider Quarterly Losses
iX Biopharma went into this earnings release with a hot share price, up more than 30% over the past three months, and a rich P/B of 32.2x that already priced in a lot of hope. The headline from Q4 is less about growth and more about pressure. Revenue for the quarter sat at about S$2.1m while the company reported a net loss of roughly S$5.0m and another quarterly loss per share. For a stock this expensive on book value, the persistence of red ink is what the market now has to digest.
Love the...